Day: October 9, 2020

MONTREAL, Oct. 09, 2020 (GLOBE NEWSWIRE) — Velan Inc.’s wholly owned subsidiary Velan ABV, located in Lucca, Italy, has been recently awarded important contracts for the supply of multiple packages of actuated and manual valves to MODEC Offshore Production Systems (Singapore) Pte. Ltd. These orders are added to those already acquired in the last 12 months for sales in excess of US$30 million and represent the continuation of Velan’s commitment and successes in FPSOs, one of the leading and most demanding O&G markets. The scope of supply consists of high and ultra-high pressure forged valves whose compact design and special construction have significantly contributed to the improvement of the Customer’s process efficiency and will also improve and facilitate the daily operation of the Customer’s facilities. Deliveries...

MONTRÉAL, 09 oct. 2020 (GLOBE NEWSWIRE) — Velan ABV, une filiale en toute propriété de Velan Inc. située dans la ville italienne de Lucca, s’est récemment vu attribuer d’importants contrats de vannes actionnées et manuelles par l’entreprise singapourienne, MODEC Offshore Production Systems Pte. Ltd. Ceux-ci s’ajoutent au bilan de contrats acquis au cours des 12 derniers mois. Totalisant plus de 30 millions de dollars US, ils représentent la continuation des engagements et des réussites de Velan dans le domaine des FPSO, l’un des marchés d’hydrocarbures les plus importants et exigeants. L’étendue des fournitures comprend des vannes forgées à haute et ultra-haute pression. La conception compacte et la construction particulières de celles-ci ont grandement contribué à l’efficacité du procédé du client et serviront également à améliorer...

Series  RIKB 23 0515 RIKS 33 0321Settlement Date  10/14/2020 10/14/2020Total Amount Allocated (MM)  10,588 2,745All Bids Awarded At (Price / Yield)  99.122 / 1.850 130.202 / 0.490Total Number of Bids Received  26 20Total Amount of All Bids Received (MM)  10,688 3,045Total Number of Successful Bids  25 17Number of Bids Allocated in Full  25 17Lowest Price / Highest Yield Allocated  99.122 / 1.850 130.202 / 0.490Highest Price / Lowest Yield Allocated  99.250 / 1.800 131.615 / 0.390Lowest Price / Highest Yield Allocated in Full  99.122 / 1.850 130.202 / 0.490Weighted Average of Successful Bids (Price/Yield)  99.204 / 1.820 130.926 / 0.439Best Bid (Price / Yield)  99.250 / 1.800 131.615 / 0.390Worst Bid (Price / Yield)  99.080 / 1.870 129.641 / 0.530Weighted Average of All Bids Received (Price /...

Flokkur  RIKB 23 0515 RIKS 33 0321Greiðslu-og uppgjörsdagur  14.10.2020 14.10.2020Samþykkt tilboð að nafnverði (m.kr.)  10.588 2.745Samþykkt (verð / ávöxtunarkrafa)  99,122 / 1,850 130,202 / 0,490Fjöldi innsendra tilboða  26 20Upphæð móttekinna tilboða að nafnverði (m.kr.)  10.688 3.045Fjöldi samþykktra tilboða  25 17Fjöldi samþykktra tilboða úthlutað að fullu  25 17Lægsta úthlutaða verð / Hæsta úthlutaða ávöxtunarkrafa  99,122 / 1,850 130,202 / 0,490Hæsta úthlutaða verð / Lægsta úthlutaða ávöxtunarkrafa  99,250 / 1,800 131,615 / 0,390Lægsta verð / Hæsta ávöxtunarkrafa úthlutað að fullu  99,122 / 1,850 130,202 / 0,490Vegið meðaltal samþykktra tilboða (verð / ávöxtunarkrafa)  99,204 / 1,820 130,926 / 0,439Besta tilboð (verð / ávöxtunarkrafa)  99,250 / 1,800 131,615 / 0,390Versta tilboð (verð / ávöxtunarkrafa)  99,080 / 1,870 129,641 / 0,530Vegið...

Data to be presented at the 5thAnnual Symposium on Hidradenitis Suppurativa Advances (SHSA)Results support clinical development of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS) and other IL-1R/TLR-driven autoimmune and inflammatory diseases, with Phase 1 trial on track for start in 2021WATERTOWN, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today announced the company will present interim data from a non-interventional trial evaluating IRAK4 expression in the skin and blood of patients with HS and atopic dermatitis (AD) as well as the effect of its lead IRAK4 degrader, KT-474, on IRAK4 levels in peripheral blood mononuclear cells (PBMC) following...

TORONTO, Oct. 09, 2020 (GLOBE NEWSWIRE) — Evergold Corp. (TSX-V: EVER, OTC: EVGUF, FRA: 5EG) (“Evergold” or the “Company”). On September 22 the Company announced the closing of the first (hard dollar-focused) tranche of its previously announced (news, August 28) non-brokered private placement along with its intention to complete a second tranche targeted primarily at flow-through funds. At the same time the Company also announced its desire to await initial assays from drilling this summer at the Company’s promising GL 1 ‘Main’ target, located on the Golden Lion property in northern British Columbia, Canada, prior to completing the second tranche of the financing.  Geochemistry labs in B.C. are seriously backed up at present and assay results are taking much longer than originally promised due to robust financing markets for juniors...

NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for AXO-AAV-GM1, an AAV9-based gene therapy delivered via a single intravenous administration that is in Phase 1/2 development for GM1 gangliosidosis. In addition to the Rare Pediatric Disease designation, AXO-AAV-GM1 has Orphan Drug designation and is the only gene therapy in clinical development for both infantile (Type I) and juvenile (Type II) GM1 gangliosidosis.“Receiving Rare Pediatric Disease Designation in addition to the previously granted Orphan Drug Designation for AXO-AAV-GM1 highlights the importance of expediting a therapy...